Healthcare
Live Price
Offline$0.0001
-50.00% today
Window Change
-97.99%
Window
Jun 23, 2025 → Apr 9, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 201 bars · Jun 23, 2025 → Apr 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TILT Holdings Inc. (TLLTF) is a Healthcare stock with a market cap of $34.75K and listed on OTC. The stock last traded around $0.00 and down 98.0% across the available one-year price window (Jun 23, 2025 → Apr 9, 2026). Baseline metrics include revenue growth of -30.3%, EPS growth of -50.0%, a dividend yield of 0.0%. What stands out right now is revenue -30.3%, EPS -50.0%, free cash flow -123.2% with operating margin -77.3% and ROIC -55.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TLLTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLLTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLLTF Max Drawdown
-99.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TLLTF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$158.4M
-21.9% YoY
FY Net Income
-$52.1M
-15.5% YoY
Free Cash Flow
$7.7M
+163.0% YoY
Revenue Growth
-30.3%
EPS Growth
-50.0%
Gross Margin
18.2%
Net Margin
-115.5%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 116M | 166M | 174M | 203M | 158M |
| Gross Profit | 20M | 19M | 38M | 58M | 59M |
| Operating Income | -69M | -43M | -29M | 272K | 5M |
| EBITDA | -46M | -25M | -65M | -17M | -30M |
| Net Income | -95M | -62M | -107M | -45M | -52M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 2M | 2M | 7M | 7M |
| Total Assets | 151M | 231M | 294M | 415M | 430M |
| Total Liabilities | 189M | 169M | 172M | 181M | 147M |
| Shareholder Equity | -37M | 62M | 121M | 234M | 283M |
| Total Debt | 130M | 110M | 106M | 98M | 85M |
| Net Debt | 127M | 108M | 104M | 92M | 78M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
+209.4% YoY
Capital Expenditures
2M
+44.9% YoY
Free Cash Flow
8M
+163.0% YoY
Key ratios
Gross Margin
18.2%
Operating Margin
-77.3%
Net Margin
-115.5%
ROE
133.4%
Debt / Equity
-1.54x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.